Skip to main content
GANX
NASDAQ Life Sciences

Gain Therapeutics Reports Q1 2026 Results with Going Concern Warning, Increased Losses, and Reduced Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.85
Mkt Cap
$77.63M
52W Low
$1.41
52W High
$4.34
52W Position info
31% above low
Off High info
57% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

GANX sits 31% above its 52-week low of $1.41.

Summary

Gain Therapeutics faces significant financial challenges, including a going concern warning, increased losses, and a short cash runway, alongside new litigation.


Key Events · Financing and Capital Events · GANX

  • Going Concern Warning Issued

    The company explicitly states that its cash and cash equivalents of $16.5 million as of March 31, 2026, will not be sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern beyond Q1 2027.

  • Increased Net Loss and Cash Burn

    Net loss for Q1 2026 increased to $5.6 million from $4.5 million in Q1 2025. Cash used in operating activities also rose to $4.7 million in Q1 2026, up from $3.8 million in the prior year period.

  • Reduced Cash Position

    Cash and cash equivalents decreased to $16.5 million as of March 31, 2026, from $20.8 million at December 31, 2025.

  • New Litigation Filed

    A new lawsuit was filed against the company and its CEO, seeking over $3.1 million in damages related to an alleged agreement to amend warrant exercise prices.


Analysis · GANX · Life Sciences

Gain Therapeutics has reported a substantial doubt about its ability to continue as a going concern, with existing cash of $16.5 million expected to fund operations only into the first quarter of 2027. The company's net loss increased to $5.6 million in Q1 2026 from $4.5 million in Q1 2025, and cash used in operating activities rose to $4.7 million from $3.8 million in the prior year. This financial distress is compounded by a new $3.1 million litigation claim against the company and its CEO. While the company continues to raise capital through its At-The-Market (ATM) program, these efforts are insufficient to resolve the immediate liquidity concerns.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GANX was trading at $1.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.6M. The 52-week trading range was $1.41 to $4.34. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GANX - Latest Insights

GANX
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $1.12 info
Change: +$0.040 (+4%) info
Market Cap: $46.306M info
GANX
Oct 01, 2026, 9:28 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.12 info
Change: -$0.620 (-36%) info
Market Cap: $46.306M info
GANX
Oct 01, 2026, 9:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.12 info
Change: -$0.6325 (-36%) info
Market Cap: $46.306M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.12 info
Change: -$0.8826 (-44%) info
Market Cap: $46.306M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.12 info
Change: -$0.940 (-46%) info
Market Cap: $46.306M info